Drugged enthusiasm

26 August 2013 By Rob Cox

The mega-biotech is paying a near-50 pct premium to buy Onyx for $10.4 bln. Investors rewarded the pluck, adding more to Amgen’s market value since it first bid than it is shelling out to seal the deal. The cocktail of revenue gains and cost cuts is a winning merger prescription.

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)